New hope for Hard-to-Treat myeloma: first human trial begins
NCT ID NCT07409246
First seen Feb 20, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This early-stage study tests an experimental drug called ABBV-438 in about 127 adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink the cancer. Participants will receive the drug through an IV, and the study will last about 5.8 years total.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City Of Hope - Atlanta. /ID# 280294
RECRUITINGNewnan, Georgia, 30265, United States
-
START Midwest /ID# 279035
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
The Cancer Institute Hospital Of JFCR /ID# 279069
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
Conditions
Explore the condition pages connected to this study.